Search
for
Sort by
Research 961–990 of 1000+
- Evaluation of the level of serum Interleukins (IL-2, IL-4, IL-15 andIL-17) and its relationship with disease severity in patients with alopecia areata
- Analyzing the role of ACE2, AR, MX1 and TMPRSS2 genetic markers for COVID-19 severity
- Chemokine C-C Motif Ligand 7 (CCL7), a Biomarker of Atherosclerosis, Is Associated with the Severity of Alopecia Areata: A Preliminary Study
- Detection of Serum Levels of Interleukins-17, 21, 6 and Tumor Necrosis Factor-α in Patients with Patchy Alopecia Areata and Their Association with Disease Severity
- Evaluation of neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, mean platelet volume, CRP and ESR with disease severity in patients with alopecia areata
- BH08 Evaluating quality-of-life measures for alopecia: a comparative analysis of Dermatology Life Quality Index and Hospital Anxiety and Depression Scale correlations with disease severity
- Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
- Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
- An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
- Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis
- Experience with oral tofacitinib in 8 adolescent patients with alopecia universalis
- Management of alopecia areata: Updates and algorithmic approach
- Cyclosporine for moderate-to-severe alopecia areata: A double-blind, randomized, placebo-controlled clinical trial of efficacy and safety
- Alefacept for Severe Alopecia Areata
- A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata
- Objective outcome measures: Collecting meaningful data on alopecia areata
- Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers
- Alopecia areata: A review
- Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents
- Treatment of alopecia areata in pre‐adolescent children with oral tofacitinib: A retrospective study
- Quality of life in patients with alopecia areata: a hospital‐based cross‐sectional study
- Low-Dose IL-2 for Treating Moderate to Severe Alopecia Areata: A 52-Week Multicenter Prospective Placebo-Controlled Study Assessing its Impact on T Regulatory Cell and NK Cell Populations
- Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience
- Dupilumab induces hair regrowth in pediatric alopecia areata: a real-world, single-center observational study
- Comparative efficacy of oral Janus kinase inhibitors and biologics in adult alopecia areata: A systematic review and Bayesian network meta‐analysis
- Quantifying Alopecia Areata via Texture Analysis to Automate the SALT Score Computation
- Dupilumab therapy for alopecia areata in pediatric patients with concomitant atopic dermatitis
- Treatment of moderate-to-severe alopecia areata in pre-adolescent children with baricitinib
- Efficacy of Postbiotics in a PRP-Like Cosmetic Product for the Treatment of Alopecia Area Celsi: A Randomized Double-Blinded Parallel-Group Study